BACKGROUND Cerebral venous sinus thrombosis(CVT)is rare cause of cerebrovascular disease.The incidence is 0.5%of all stroke.The majority of affected patients are young adults(mean age:35-40 years)with mild to moderate...BACKGROUND Cerebral venous sinus thrombosis(CVT)is rare cause of cerebrovascular disease.The incidence is 0.5%of all stroke.The majority of affected patients are young adults(mean age:35-40 years)with mild to moderate disabilities.Poor outcome with severe disability is seen in 13%of cases.Early diagnosis and treatment are important for good outcomes and preventing complications.Treatment options are limited and mostly based on consensus.NeuroAiD II™(MLC901;Moleac Pte,Ltd,Singapore)has a potential beneficial role in post-stroke recovery,by aiding the natural brain recovery process.CASE SUMMARY MLC901 consists of nine natural herbal ingredients.Studies have shown its safety profile and aid in post stroke recovery.The aim of this case series was to demonstrate the potential role of MLC901 in stroke recovery of patients with cerebral venous sinus thrombosis(CVST)who received MLC901 in addition to standard of care.The prescribed dose of MLC901 is 400 mg/cap two capsules,three times a day.Data from these patients were prospectively collected at baseline and at monthly visits,for a duration of 3 mo.Outcome measures included adherence to therapy,side effects,National Institutes of Health Stroke Scale,Glasgow Coma Scale,modified Rankin Scale,and the Short Orientation-Memory-Concentration Test.MLC901 was well tolerated and no side effects were reported.All patients were stable with improved condition.CONCLUSION This case series highlights the potential therapeutic effects of MLC901 on CVST and provides support for further studies.展开更多
Background: Blocking the Rho A/ROCK Ⅱ/MLC 2(Ras homolog gene family member A/Rho kinase Ⅱ/myosin light chain 2) signaling pathway can initiate neuroprotective mechanisms against neurological diseases such as stroke,...Background: Blocking the Rho A/ROCK Ⅱ/MLC 2(Ras homolog gene family member A/Rho kinase Ⅱ/myosin light chain 2) signaling pathway can initiate neuroprotective mechanisms against neurological diseases such as stroke, cerebral ischemia, and subarachnoid hemorrhage. Nevertheless, it is not clear whether and how disrupting the Rho A/ROCK Ⅱ/MLC 2 signaling pathway changes the pathogenic processes of the blood–brain barrier(BBB) after intracerebral hemorrhage(ICH). The present investigation included the injection of rat caudal vein blood into the basal ganglia area to replicate the pathophysiological conditions caused by ICH. Methods: Scalp acupuncture(SA) therapy was performed on rats with ICH at the acupuncture point “Baihui”-penetrating “Qubin,” and the ROCK selective inhibitor fasudil was used as a positive control to evaluate the inhibitory effect of acupuncture on the Rho A/ROCK Ⅱ/MLC 2 signaling pathway. Post-assessments included neurological deficits, brain edema, Evans blue extravasation, Western blot, quantitative polymerase chain reaction, and transmission electron microscope imaging. Results: We found that ROCK Ⅱ acts as a promoter of the Rho A/ROCK Ⅱ/MLC 2 signaling pathway, and its expression increased at 6 h after ICH, peaked at 3 days, and then decreased at 7 days after ICH, but was still higher than the preintervention level. According to some experimental results, although 3 days is the peak, 7 days is the best time point for acupuncture treatment. Starting from 6 h after ICH, the neurovascular structure and endothelial cell morphology around the hematoma began to change. Based on the changes in the promoter ROCK Ⅱ, a 7-day time point was selected as the breakthrough point for treating ICH model rats in the main experiment. The results of this experiment showed that both SA at “Baihui”-penetrating “Qubin” and treatment with fasudil could improve the expression of endothelial-related proteins by inhibiting the Rho A/ROCK Ⅱ/MLC 2 signaling pathway and reduce neurological dysfunction, brain edema, and BBB permeability in rats. Conclusion: This study found that these experimental data indicated that SA at “Baihui”-penetrating “Qubin” could preserve BBB integrity and neurological function recovery after ICH by inhibiting Rho A/ROCK Ⅱ/MLC 2 signaling pathway activation and by regulating endothelial cell–related proteins.展开更多
Utilizing commercial off-the-shelf(COTS) components in satellites has received much attention due to the low cost. However, commercial memories suffer severe reliability problems in radiation environments. This paper ...Utilizing commercial off-the-shelf(COTS) components in satellites has received much attention due to the low cost. However, commercial memories suffer severe reliability problems in radiation environments. This paper studies the low-density parity-check(LDPC) coding scheme for improving the reliability of multi-level-cell(MLC) NAND Flash memory in radiation environments. Firstly, based on existing physical experiment works, we introduce a new error model for heavyion irradiations; secondly, we explore the optimization of writing voltage allocation to maximize the capacity of the storage channel; thirdly, we design the degree distribution of LDPC codes that is specially suitable for the proposed model; finally, we propose a joint detection-decoding scheme based on LDPC codes, which estimates the storage channel state and executes an adaptive log-likelihood ratio(LLR) calculation to achieve better performance. Simulation results show that, compared with the conventional LDPC coding scheme, the proposed scheme may almost double the lifetime of the MLC NAND Flash memory in radiation environments.展开更多
为了提高MLC NAND Flash的抗误码性能,该文提出一种基于优化缩短极化码的MLC NAND Flash差错控制方法。优化缩短极化码通过优化删减图样得到,首先通过比特翻转重排序的方式得到基本删减图样,进而选择具有更低信道容量的冻结比特组成优...为了提高MLC NAND Flash的抗误码性能,该文提出一种基于优化缩短极化码的MLC NAND Flash差错控制方法。优化缩短极化码通过优化删减图样得到,首先通过比特翻转重排序的方式得到基本删减图样,进而选择具有更低信道容量的冻结比特组成优化删减图样,使得到的删减比特全为冻结比特,可以显著提高删减算法的纠错性能。同时,根据MLC单元错误的不对称性,采用码率自适应的码字对FLASH中MSB和LSB进行不等错误保护。仿真结果表明:当误帧率为310-时,优化缩短极化码较相同码长的LDPC码和基本缩短极化码分别约有3.72~5.89 d B和1.47~3.49 d B增益;相比基于同一码率的优化缩短极化码方案,不等错误保护的差错控制方案获得约0.25 d B增益。展开更多
文摘BACKGROUND Cerebral venous sinus thrombosis(CVT)is rare cause of cerebrovascular disease.The incidence is 0.5%of all stroke.The majority of affected patients are young adults(mean age:35-40 years)with mild to moderate disabilities.Poor outcome with severe disability is seen in 13%of cases.Early diagnosis and treatment are important for good outcomes and preventing complications.Treatment options are limited and mostly based on consensus.NeuroAiD II™(MLC901;Moleac Pte,Ltd,Singapore)has a potential beneficial role in post-stroke recovery,by aiding the natural brain recovery process.CASE SUMMARY MLC901 consists of nine natural herbal ingredients.Studies have shown its safety profile and aid in post stroke recovery.The aim of this case series was to demonstrate the potential role of MLC901 in stroke recovery of patients with cerebral venous sinus thrombosis(CVST)who received MLC901 in addition to standard of care.The prescribed dose of MLC901 is 400 mg/cap two capsules,three times a day.Data from these patients were prospectively collected at baseline and at monthly visits,for a duration of 3 mo.Outcome measures included adherence to therapy,side effects,National Institutes of Health Stroke Scale,Glasgow Coma Scale,modified Rankin Scale,and the Short Orientation-Memory-Concentration Test.MLC901 was well tolerated and no side effects were reported.All patients were stable with improved condition.CONCLUSION This case series highlights the potential therapeutic effects of MLC901 on CVST and provides support for further studies.
基金supported by the National Natural Science Foundation of China(numbers:81774416 and 81473764)。
文摘Background: Blocking the Rho A/ROCK Ⅱ/MLC 2(Ras homolog gene family member A/Rho kinase Ⅱ/myosin light chain 2) signaling pathway can initiate neuroprotective mechanisms against neurological diseases such as stroke, cerebral ischemia, and subarachnoid hemorrhage. Nevertheless, it is not clear whether and how disrupting the Rho A/ROCK Ⅱ/MLC 2 signaling pathway changes the pathogenic processes of the blood–brain barrier(BBB) after intracerebral hemorrhage(ICH). The present investigation included the injection of rat caudal vein blood into the basal ganglia area to replicate the pathophysiological conditions caused by ICH. Methods: Scalp acupuncture(SA) therapy was performed on rats with ICH at the acupuncture point “Baihui”-penetrating “Qubin,” and the ROCK selective inhibitor fasudil was used as a positive control to evaluate the inhibitory effect of acupuncture on the Rho A/ROCK Ⅱ/MLC 2 signaling pathway. Post-assessments included neurological deficits, brain edema, Evans blue extravasation, Western blot, quantitative polymerase chain reaction, and transmission electron microscope imaging. Results: We found that ROCK Ⅱ acts as a promoter of the Rho A/ROCK Ⅱ/MLC 2 signaling pathway, and its expression increased at 6 h after ICH, peaked at 3 days, and then decreased at 7 days after ICH, but was still higher than the preintervention level. According to some experimental results, although 3 days is the peak, 7 days is the best time point for acupuncture treatment. Starting from 6 h after ICH, the neurovascular structure and endothelial cell morphology around the hematoma began to change. Based on the changes in the promoter ROCK Ⅱ, a 7-day time point was selected as the breakthrough point for treating ICH model rats in the main experiment. The results of this experiment showed that both SA at “Baihui”-penetrating “Qubin” and treatment with fasudil could improve the expression of endothelial-related proteins by inhibiting the Rho A/ROCK Ⅱ/MLC 2 signaling pathway and reduce neurological dysfunction, brain edema, and BBB permeability in rats. Conclusion: This study found that these experimental data indicated that SA at “Baihui”-penetrating “Qubin” could preserve BBB integrity and neurological function recovery after ICH by inhibiting Rho A/ROCK Ⅱ/MLC 2 signaling pathway activation and by regulating endothelial cell–related proteins.
基金supported by the National Basic Research Project of China(973)(2013CB329006)National Natural Science Foundation of China(NSFC,91538203)the new strategic industries development projects of Shenzhen City(JCYJ20150403155812833)
文摘Utilizing commercial off-the-shelf(COTS) components in satellites has received much attention due to the low cost. However, commercial memories suffer severe reliability problems in radiation environments. This paper studies the low-density parity-check(LDPC) coding scheme for improving the reliability of multi-level-cell(MLC) NAND Flash memory in radiation environments. Firstly, based on existing physical experiment works, we introduce a new error model for heavyion irradiations; secondly, we explore the optimization of writing voltage allocation to maximize the capacity of the storage channel; thirdly, we design the degree distribution of LDPC codes that is specially suitable for the proposed model; finally, we propose a joint detection-decoding scheme based on LDPC codes, which estimates the storage channel state and executes an adaptive log-likelihood ratio(LLR) calculation to achieve better performance. Simulation results show that, compared with the conventional LDPC coding scheme, the proposed scheme may almost double the lifetime of the MLC NAND Flash memory in radiation environments.
文摘为了提高MLC NAND Flash的抗误码性能,该文提出一种基于优化缩短极化码的MLC NAND Flash差错控制方法。优化缩短极化码通过优化删减图样得到,首先通过比特翻转重排序的方式得到基本删减图样,进而选择具有更低信道容量的冻结比特组成优化删减图样,使得到的删减比特全为冻结比特,可以显著提高删减算法的纠错性能。同时,根据MLC单元错误的不对称性,采用码率自适应的码字对FLASH中MSB和LSB进行不等错误保护。仿真结果表明:当误帧率为310-时,优化缩短极化码较相同码长的LDPC码和基本缩短极化码分别约有3.72~5.89 d B和1.47~3.49 d B增益;相比基于同一码率的优化缩短极化码方案,不等错误保护的差错控制方案获得约0.25 d B增益。
